U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H6O2S
Molecular Weight 154.186
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THIOSALICYLIC ACID

SMILES

OC(=O)C1=CC=CC=C1S

InChI

InChIKey=NBOMNTLFRHMDEZ-UHFFFAOYSA-N
InChI=1S/C7H6O2S/c8-7(9)5-3-1-2-4-6(5)10/h1-4,10H,(H,8,9)

HIDE SMILES / InChI

Molecular Formula C7H6O2S
Molecular Weight 154.186
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Thiosalicylic acid is an analgesic and anti-inflammatory agent. It is used (in form of sodium salt) to relieve symptoms of acute gout, painful musculoskeletal conditions, osteoarthritis and rheumatic fever. The drug exerts its action by inhibiting prostaglandin synthesis. Thiosalicylic acid usage is associated with the risk of contact dermatitis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
REXOLATE

Approved Use

To relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever.
Palliative
REXOLATE

Approved Use

To relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever.
Palliative
REXOLATE

Approved Use

To relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever.
Primary
REXOLATE

Approved Use

To relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever.
PubMed

PubMed

TitleDatePubMed
Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells.
2011-01-20
14-(1,3-Benzodioxol-5-yl)-7,14-dihydro-dibenzo[a,j]acridine.
2010-11-06
Ultraviolet treatment and biodegradation of dibenzothiophene: Identification and toxicity of products.
2010-11
Low molecular weight thiols reduce thimerosal neurotoxicity in vitro: modulation by proteins.
2010-10-29
Field-assisted synthesis of SERS-active silver nanoparticles using conducting polymers.
2010-08
Intercalation of anionic organic ultraviolet ray absorbers into layered zinc hydroxide nitrate.
2010-07-01
Responsiveness of human monocyte-derived dendritic cells to thimerosal and mercury derivatives.
2010-07
2-[(2-Carboxy-phen-yl)disulfan-yl]benzoic acid-4,4'-bipyridyl N,N'-dioxide (1/2).
2010-05-26
Sensitization effect of thimerosal is mediated in vitro via reactive oxygen species and calcium signaling.
2010-03-17
Poly[(dimethyl-formamide)(μ(4)-2,2'-sulfanediyldibenzoato)nickel(II)].
2010-03-06
Electrochemical scanning tunneling spectroscopy of redox-active molecules bound by Au-C bonds.
2010-03-03
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
2010-01
Mercury exposure, nutritional deficiencies and metabolic disruptions may affect learning in children.
2009-10-27
Synthesis and characterization of thiosalicylic acid stabilized gold nanoparticles.
2009-09-15
2-[(2-Carboxy-phen-yl)sulfan-yl]acetic acid.
2009-09-05
The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
2009-07
Expression of metallothionein mRNAs on mouse cerebellum microglia cells by thimerosal and its metabolites.
2009-06-30
Ultrasonic-assisted precolumn derivatization-HPLC determination of acrylamide formed in Radix Asparagi during heating process.
2009-05-01
Zinc ions cause the thimerosal-induced signal of fluorescent calcium probes in lymphocytes.
2009-02
[1,2-Bis(diphenyl-phosphino)ethane-κP,P'](2-carboxyl-atothio-phenolato-κO,S)nickel(II) methanol solvate.
2009-01-08
Thimerosal and the relevance of patch-test reactions in children.
2008-10-11
Determination of acrylamide during roasting of coffee.
2008-08-13
Development of a stable isotope dilution assay for the quantitation of glycidamide and its application to foods and model systems.
2008-08-13
Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries.
2008-08
In vitro-refolding of a single-chain Fv fragment in the presence of heteroaromatic thiols.
2008-04-30
Removal of malodorous organic sulfides with molecular oxygen and visible light over metal phthalocyanine.
2008-03-21
Synthesis and biological evaluation of sulfur-containing cinnamate and salicylate derivatives.
2008-03
Cleavage of focal adhesion kinase is an early marker and modulator of oxidative stress-induced apoptosis.
2008-01-10
Competing ligand exchange-solid phase extraction method for the determination of the complexation of dissolved inorganic mercury (II) in natural waters.
2007-08-29
Field amplified sample injection-capillary electrophoresis-tandem mass spectrometry for the analysis of acrylamide in foodstuffs.
2007-08-03
Heterocycles [h]fused onto 4-oxoquinoline-3-carboxylic acid, part IV. Convenient synthesis of substituted hexahydro [1,4]thiazepino[2,3-h]quinoline-9-carboxylic acid and its tetrahydroquino[7,8-b]benzothiazepine homolog.
2007-07-27
Relationship between redox activity and chemical speciation of size-fractionated particulate matter.
2007-06-07
Effect of subinhibitory concentration of some established and experimental antifungal compounds on the germ tube formation in Candida albicans.
2007
Effect of ring substitution position on the structural conformation of mercaptobenzoic acid self-assembled monolayers on Au(111).
2006-12-19
Analysis of acrylamide in food products by in-line preconcentration capillary zone electrophoresis.
2006-09-29
Thimerosal induces apoptosis and G2/M phase arrest in human leukemia cells.
2006-09
Analysis of acrylamide in food samples by capillary zone electrophoresis.
2006-07-07
Uncoupling of ATP-mediated calcium signaling and dysregulated interleukin-6 secretion in dendritic cells by nanomolar thimerosal.
2006-07
Self-assembly of dialkyltin moieties and mercaptobenzoic acid into macrocyclic complexes with hydrophobic "pseudo-cage" or double-cavity structures: supramolecular infrastructures involving intermolecular C-H...S weak hydrogen bonds and pi-pi interactions.
2005-12-23
Determination of mercury complexation in coastal and estuarine waters using competitive ligand exchange method.
2005-09-01
Quantitative description of the deactivation channels of the first excited singlet state of 2- and 4-thiosalicylic acids.
2005-07-28
Chelating sorbents based on silica gel and their application in atomic spectrometry.
2005-03
One-pot synthesis of benzo[e]1,4-oxathiepin-5-ones under solvent-free condition via self-promoted thiolysis of 1,2-epoxides.
2004-12-10
Determination of thiocyl in biological samples by liquid chromatography with ThioGlo 3 derivatization.
2004-10-05
A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM).
2004-07
Using model complexes to augment and advance metalloproteinase inhibitor design.
2004-05-17
Lactic acid triggers, in vitro, thiomersal to degrade protein in the presence of PLGA microspheres.
2004-04-01
Development of a direct-binding chloramphenicol sensor based on thiol or sulfide mediated self-assembled antibody monolayers.
2004-02-15
Preconcentration of lead with Amberlite XAD-2 and Amberlite XAD-7 based chelating resins for its determination by flame atomic absorption spectrometry.
2002-03-11
Cytotoxicity of Triorganophosphinegold(I) n-Mercaptobenzoates, n = 2, 3 and 4.
2002
Patents

Sample Use Guides

Acute gout: initial dose is 100 mg every 3 to 4 hours for 2 days, then 100 mg daily. Painful musculoskeletal conditions: 50 to 100 mg daily or every other day. Osteoarthritis: 10 mg 3 times/week for several weeks then once a week, usually up to a total dosage of 2.5 g. Rheumatic fever: initial dose is 100 to 150 mg every 4 to 8 hours for 3 days, then 100 mg two times daily.
Route of Administration: Other
In Vitro Use Guide
Human platelets were incubated with thiosalicylic acid at 0.5 mM for 3 min in the presence of 1,2 and 1,3-glyceryl dinitrate. A concentration-dependent inhibition of platelet aggregation was observed.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:52:56 GMT 2025
Edited
by admin
on Mon Mar 31 17:52:56 GMT 2025
Record UNII
CIP6LXN5XW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THIOSALICYLIC ACID
INCI   MI   WHO-DD  
INCI  
Official Name English
NSC-2184
Preferred Name English
Thiosalicylic acid [WHO-DD]
Common Name English
O-SULFHYDRYLBENZOIC ACID
Systematic Name English
THIOSALICYLATE
Systematic Name English
2-MERCAPTOBENZOIC ACID
Systematic Name English
THIOSALICYLIC ACID [USP IMPURITY]
Common Name English
THIOSALICYLIC ACID [MI]
Common Name English
NSC-660640
Code English
2-THIOSALICYLIC ACID [HSDB]
Common Name English
Classification Tree Code System Code
EPA PESTICIDE CODE 78903
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
NCI_THESAURUS C257
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
Code System Code Type Description
NSC
660640
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
WIKIPEDIA
THIOSALICYLIC ACID
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
MESH
C441201
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
NSC
2184
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
PUBCHEM
5443
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
RXCUI
322165
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
EPA CompTox
DTXSID4049032
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
CHEBI
59124
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
RXCUI
91099
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
ALTERNATIVE
FDA UNII
CIP6LXN5XW
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
CHEBI
59127
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
MERCK INDEX
m10783
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY Merck Index
CAS
147-93-3
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
HSDB
2739
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
DRUG BANK
DB14026
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
NCI_THESAURUS
C87327
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
SMS_ID
100000183747
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
ECHA (EC/EINECS)
205-704-3
Created by admin on Mon Mar 31 17:52:56 GMT 2025 , Edited by admin on Mon Mar 31 17:52:56 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY